Novel pathophysiological insights into CAR-T cell associated neurotoxicity
Chimeric antigen receptor (CAR) T cell therapy represents a scientific breakthrough in the treatment of advanced hematological malignancies. It relies on cell engineering to direct the powerful cytotoxic T-cell activity toward tumor cells. Nevertheless, these highly powerful cell therapies can trigg...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1108297/full |
| _version_ | 1811158333047963648 |
|---|---|
| author | Vassilis Genoud Vassilis Genoud Denis Migliorini Denis Migliorini Denis Migliorini Denis Migliorini |
| author_facet | Vassilis Genoud Vassilis Genoud Denis Migliorini Denis Migliorini Denis Migliorini Denis Migliorini |
| author_sort | Vassilis Genoud |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR) T cell therapy represents a scientific breakthrough in the treatment of advanced hematological malignancies. It relies on cell engineering to direct the powerful cytotoxic T-cell activity toward tumor cells. Nevertheless, these highly powerful cell therapies can trigger substantial toxicities such as cytokine release syndrome (CRS) and immune cell-associated neurological syndrome (ICANS). These potentially fatal side effects are now better understood and managed in the clinic but still require intensive patient follow-up and management. Some specific mechanisms seem associated with the development of ICANS, such as cytokine surge caused by activated CAR-T cells, off-tumor targeting of CD19, and vascular leak. Therapeutic tools are being developed aiming at obtaining better control of toxicity. In this review, we focus on the current understanding of ICANS, novel findings, and current gaps. |
| first_indexed | 2024-04-10T05:22:44Z |
| format | Article |
| id | doaj.art-afad2042b6c7481dbd112536677b661d |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-10T05:22:44Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-afad2042b6c7481dbd112536677b661d2023-03-08T06:52:42ZengFrontiers Media S.A.Frontiers in Neurology1664-22952023-03-011410.3389/fneur.2023.11082971108297Novel pathophysiological insights into CAR-T cell associated neurotoxicityVassilis Genoud0Vassilis Genoud1Denis Migliorini2Denis Migliorini3Denis Migliorini4Denis Migliorini5Department of Oncology, University Hospital of Geneva, Geneva, SwitzerlandCenter for Translational Research in Onco-Haematology, University of Geneva, Geneva, SwitzerlandDepartment of Oncology, University Hospital of Geneva, Geneva, SwitzerlandCenter for Translational Research in Onco-Haematology, University of Geneva, Geneva, SwitzerlandBrain Tumor and Immune Cell Engineering Laboratory, AGORA Cancer Research Center, Lausanne, SwitzerlandSwiss Cancer Center Léman (SCCL), Lausanne and Geneva, Geneva, SwitzerlandChimeric antigen receptor (CAR) T cell therapy represents a scientific breakthrough in the treatment of advanced hematological malignancies. It relies on cell engineering to direct the powerful cytotoxic T-cell activity toward tumor cells. Nevertheless, these highly powerful cell therapies can trigger substantial toxicities such as cytokine release syndrome (CRS) and immune cell-associated neurological syndrome (ICANS). These potentially fatal side effects are now better understood and managed in the clinic but still require intensive patient follow-up and management. Some specific mechanisms seem associated with the development of ICANS, such as cytokine surge caused by activated CAR-T cells, off-tumor targeting of CD19, and vascular leak. Therapeutic tools are being developed aiming at obtaining better control of toxicity. In this review, we focus on the current understanding of ICANS, novel findings, and current gaps.https://www.frontiersin.org/articles/10.3389/fneur.2023.1108297/fullimmune effector cell-associated neurotoxicity syndrome (ICANS)neurotoxicitycellular therapieschimeric antigen receptor (CAR) T cellscytokine release syndrome (CRS) |
| spellingShingle | Vassilis Genoud Vassilis Genoud Denis Migliorini Denis Migliorini Denis Migliorini Denis Migliorini Novel pathophysiological insights into CAR-T cell associated neurotoxicity Frontiers in Neurology immune effector cell-associated neurotoxicity syndrome (ICANS) neurotoxicity cellular therapies chimeric antigen receptor (CAR) T cells cytokine release syndrome (CRS) |
| title | Novel pathophysiological insights into CAR-T cell associated neurotoxicity |
| title_full | Novel pathophysiological insights into CAR-T cell associated neurotoxicity |
| title_fullStr | Novel pathophysiological insights into CAR-T cell associated neurotoxicity |
| title_full_unstemmed | Novel pathophysiological insights into CAR-T cell associated neurotoxicity |
| title_short | Novel pathophysiological insights into CAR-T cell associated neurotoxicity |
| title_sort | novel pathophysiological insights into car t cell associated neurotoxicity |
| topic | immune effector cell-associated neurotoxicity syndrome (ICANS) neurotoxicity cellular therapies chimeric antigen receptor (CAR) T cells cytokine release syndrome (CRS) |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2023.1108297/full |
| work_keys_str_mv | AT vassilisgenoud novelpathophysiologicalinsightsintocartcellassociatedneurotoxicity AT vassilisgenoud novelpathophysiologicalinsightsintocartcellassociatedneurotoxicity AT denismigliorini novelpathophysiologicalinsightsintocartcellassociatedneurotoxicity AT denismigliorini novelpathophysiologicalinsightsintocartcellassociatedneurotoxicity AT denismigliorini novelpathophysiologicalinsightsintocartcellassociatedneurotoxicity AT denismigliorini novelpathophysiologicalinsightsintocartcellassociatedneurotoxicity |